Search
Meet Gert Ossenkoppele, our Volunteer of the Month
Can you tell us what you do for EHA and when you started? How did you became a volunteer? Who helped/encouraged you to become one?
I am lucky to be one of the first members of the EHA (member number 34).…
Evidence and policy to ensure good clinical practice
Interview with Vinay Prasad MD MPH by Heiko Becker MD, on behalf of YoungEHA
Leaders in the field that have the potential to make a difference, that challenge the way we are doing things, who push our perspective out of our…
EHA at ICH meeting: Excessive bureaucracy harms patient safety and innovation
To solicit input from a wide range of non-ICH members about the revision of ICH E8(R1), ICH held a Public Meeting on ICH E8(R1) “General Considerations for Clinical Studies” (Silver Spring, USA, October 31, 2019).
Read moreEHA Issues Recommendations on Mild to Moderate Bleeding Disorders
HemaSphere presents first in a series of Consensus Reports on Diagnosis of Inherited Bleeding Problems
For hematologists, it can be challenging to make the correct diagnosis in patients with bleeding problems – or even to determine whether there is any bleeding…
Current status of the Clinical Trials Regulation
HemAffairs Article #2 – June 2019
In 2014 the European Parliament approved the Clinical Trials Regulation (CTR) that is supposed to replace the Clinical Trials Directive (CTD) from 2001. Five years later, the regulation has not yet become applicable.
“Follow your dreams! Go for it!” – Verena Gaidzik, woman in hematology/EHA volunteer
Verena Gaidzik is a physician scientist in the department of Internal Medicine III (Head: Prof. Dr. Hartmut Döhner) at the University Hospital of Ulm. She has board certifications in internal medicine, hematology and oncology as well as palliative medicine.
Read moreEHA-funded study in The Lancet Haematology: Economic Burden of Blood Disorders in EU is €23 billion
In Europe blood disorders affect around 80 million people. The total cost of blood disorders consists of healthcare expenditure (€15. 6 billion), productivity loss due to illness and mortality (€5. 6 billion), and the costs of informal care (€1.
Read moreTreatment and survival of patients with chronic myeloid leukemia (CML) in Europe
Since the introduction of tyrosine kinase inhibitors into the treatment of CML survival times have greatly improved.
Read more